广告
加载中

资生堂旗下品牌进美容院 为线下和高端化紧急“自救”?

亿邦动力 2026-03-09 21:35
亿邦动力 2026/03/09 21:35

邦小白快读

EN
全文速览

文章重点介绍了资生堂通过合作自救的关键信息和实操干货。

1. 资生堂旗下品牌RQ律曜首次与美丽田园合作进入院线渠道,推出“光感透白”高端护理项目,旨在应对中国市场线下渠道下滑和高端化需求。

2. 财报显示,2025年资生堂净销售额9,699.92亿日元,同比降2.08%;归母净亏损406.8亿日元,同比降276.21%,但销售成本连续三年下降至2,269.89亿日元,毛利率达76.60%创六年新高,核心营业利润445.2亿日元同比增22.45%。

3. 中国市场线下渠道拖累业绩,仅第三季度增长,其余季度下滑,电商渠道全年增长;高端品牌加速增长,第四季度由高端品牌带动,双11价格战不影响趋势。

4. RQ律曜产品价格249元至9,900元,美丽田园2025年收入超30亿元增16%,收购思妍丽后占据行业前三,提供合作模式可借鉴。

文章聚焦品牌营销、渠道建设和高端化趋势的干货内容。

1. 品牌渠道建设方面,资生堂通过战略合作将RQ律曜入驻美丽田园院线渠道,拓展线下高端市场,应对电商增长和线下下滑的失衡。

2. 品牌定价和价格竞争上,RQ律曜医美线主原料重组胶原蛋白价格249-9,900元,护肤品线单品480元及以上,定位高端;高端化在财报中多次提及为增长动力,双11价格战不影响品牌溢价。

3. 产品研发涉及RQ律曜本土化品牌,依托上海第九人民医院与创健医疗科研,开发医美和护肤产品线;消费趋势显示中国高端化妆品需求增加,用户行为倾向于高端护理。

4. 用户行为观察揭示线下渠道两位数下滑,但高端项目合作可吸引消费者,美丽田园业绩增长说明渠道潜力。

文章解析了市场机会、风险提示和合作模式的实用干货。

1. 增长市场机会源于高端化趋势,资生堂第四季度增长由高端品牌带动,美丽田园2025年收入超30亿元增16%,经调整净利润超3.8亿元增40%,显示美容行业扩张潜力;消费需求变化体现高端护理需求上升,RQ律曜合作项目契合此点,提供可学习点。

2. 事件应对措施和风险提示包括线下渠道拖累(第一季度、第二季度下滑两位数,第四季度低个位数下滑),但电商渠道全年增长;资生堂中国业务核心营业利润虽跌75亿日元,仍达645.25亿日元,提示需规避线下风险,优先线上与高端合作;政策解读无直接涉及,但合作扶持如资生堂与美丽田园战略合作提供新路径。

3. 最新商业模式和合作方式涵盖美丽田园收购思妍丽扩充版图,占据行业前三;卖家可借鉴此类合作,或通过院线渠道提升业绩。

文章提供产品需求、商业机会和数字化启示的干货信息。

1. 产品生产和设计需求涉及RQ律曜医美线使用重组胶原蛋白作为主要原料,护肤品线覆盖卸妆、修护、抗老等功能,设计需高端定位,价格区间249-9,900元,强调科技成分如上海第九人民医院科研背景。

2. 商业机会存在于资生堂合作自救中,工厂可参与高端产品供应链,如重组胶原蛋白应用;美丽田园收购思妍丽后规模扩大,2025年收入超30亿元增16%,提供合作入口机会。

3. 推进数字化和电商的启示源于财报中电商渠道全年增长,而线下渠道下滑,提示工厂需优化线上渠道;资生堂毛利率76.60%新高反映成本控制,建议工厂学习成本降低策略。

文章揭示行业趋势、客户痛点和解决方案的关键干货。

1. 行业发展趋势显示高端化妆品需求加速,资生堂财报强调高端品牌增长;美丽田园收购思妍丽后成龙头,年收入超30亿元增16%,反映美容行业整合趋势。

2. 客户痛点主要为线下渠道拖累业绩,资生堂中国市场线下多数季度两位数下滑,电商增长形成对比;资生堂净亏损加大,提示服务需提升效率以应对。

3. 解决方案包括资生堂与美丽田园合作进入院线渠道,推出高端项目应对痛点;新技术方面,RQ律曜依托上海第九人民医院科研,提供科技护肤模型;服务商可参考此方案解决客户渠道挑战。

文章讨论平台需求、最新做法和风险管理的干货内容。

1. 商业对平台的需求和问题体现在资生堂线下渠道下滑严重,电商平台表现强劲,平台需提供增长支持;美丽田园作为平台商,需规避线下风险,而2025年净利润超3.4亿元增34%显示运营优势。

2. 平台的最新做法和招商包括美丽田园收购思妍丽100%股份,扩充版图至行业前三,并推出高端护理项目合作;资生堂战略合作提供招商机会,吸引新品牌入驻院线渠道。

3. 运营管理和风向规避上,平台需学习美丽田园的正面盈利增长(收入增16%),同时应对价格战和渠道不平衡;风险提示线下市场不稳定,但高端化趋势为风向,平台可优先发展高价值业务。

文章分析产业动向、新问题和商业模式的干货信息。

1. 产业新动向包括高端化妆品需求加速,资生堂财报多次提及高端品牌增长;美丽田园收购思妍丽后垄断前三,2025年收入增16%,反映行业整合趋势。

2. 新问题涉及线下渠道持续下滑(季度性两位数降幅),电商增长对立,政策法规无直接提及,但启示建议优化渠道结构;资生堂净亏损增大,核心营业利润矛盾(中国业务利润跌但仍是最高板块),提示政策需支持自救措施。

3. 商业模式如资生堂与美丽田园战略合作、RQ律曜产品线定位高端,提供研究案例;研究者可探讨此类合作对产业的影响和可复制性。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

The article highlights Shiseido's self-rescue strategy through strategic partnerships, focusing on key moves and practical insights.

1. Shiseido's brand RQ Lüyao partnered with Beauty Farm to enter the salon channel for the first time, launching the high-end "Brightening & Whitening" treatment program to address declining offline sales and rising demand for premium products in China.

2. Shiseido's 2025 financial report shows net sales of ¥969.992 billion (down 2.08% YoY) and a net loss of ¥40.68 billion (down 276.21% YoY). However, cost of sales fell for three consecutive years to ¥226.989 billion, pushing gross margin to a six-year high of 76.60%, while core operating profit rose 22.45% to ¥44.52 billion.

3. Offline channels in China dragged down performance, with growth only in Q3; e-commerce grew throughout the year. Premium brands accelerated growth in Q4, unaffected by Double 11 price wars.

4. RQ Lüyao products are priced between ¥249 and ¥9,900. Beauty Farm’s 2025 revenue exceeded ¥3 billion (up 16% YoY), and after acquiring Siyanli, it ranks among the top three industry players—offering a replicable partnership model.

The article focuses on brand marketing, channel expansion, and premiumization trends.

1. Shiseido expanded RQ Lüyao into Beauty Farm’s salon channel to target the high-end offline market, countering the imbalance between e-commerce growth and offline decline.

2. RQ Lüyao’s medical aesthetic line (priced ¥249–9,900) uses recombinant collagen, while its skincare line starts at ¥480, reinforcing a premium positioning. Premiumization is repeatedly cited as a growth driver, with Double 11 price wars not affecting brand premium.

3. RQ Lüyao leverages R&D collaborations with Shanghai Ninth People’s Hospital and Chuangjian Medical for localized product development. Consumer trends show growing demand for high-end cosmetics and premium skincare services.

4. Offline channels saw double-digit declines, but premium collaborations like Shiseido’s with Beauty Farm attract consumers, indicating channel potential.

The article analyzes market opportunities, risks, and partnership models for sellers.

1. Growth opportunities lie in premiumization: Shiseido’s Q4 growth was driven by high-end brands, and Beauty Farm’s 2025 revenue surpassed ¥3 billion (up 16% YoY), showing industry expansion potential. Rising demand for premium treatments makes RQ Lüyao’s collaboration a reference point.

2. Risk warnings include offline channel declines (double-digit drops in Q1 and Q2, low single-digit in Q4), though e-commerce grew consistently. Shiseido’s China operating profit fell ¥7.5 billion but remained high at ¥64.525 billion, suggesting prioritizing online and premium collaborations.

3. New business models include Beauty Farm’s acquisition of Siyanli, making it a top-three player. Sellers can learn from such partnerships or leverage salon channels to boost performance.

The article offers insights on product demand, business opportunities, and digital transformation.

1. RQ Lüyao’s medical aesthetic line uses recombinant collagen, while skincare covers cleansing, repair, and anti-aging. Products are high-end (¥249–9,900) and emphasize scientific ingredients, such as those developed with Shanghai Ninth People’s Hospital.

2. Opportunities exist in supplying premium products, e.g., recombinant collagen applications. Beauty Farm’s post-acquisition growth (revenue over ¥3 billion, up 16%) offers partnership openings.

3. Digital and e-commerce insights: offline channels declined while e-commerce grew, suggesting factories optimize online channels. Shiseido’s 76.60% gross margin reflects cost control—a strategy factories can adopt.

The article reveals industry trends, client pain points, and solutions.

1. High-end cosmetics demand is accelerating, per Shiseido’s earnings. Beauty Farm’s acquisition of Siyanli made it a leader, with revenue exceeding ¥3 billion (up 16%), reflecting industry consolidation.

2. Client pain points include offline channel struggles (double-digit declines in most quarters), contrasting with e-commerce growth. Shiseido’s widening net loss highlights the need for efficiency improvements.

3. Solutions include Shiseido-Beauty Farm’s salon channel partnership for premium services. RQ Lüyao’s hospital-backed R&D offers a tech-driven skincare model, providing a reference for addressing channel challenges.

The article discusses platform needs, latest practices, and risk management.

1. Brands like Shiseido need platform support due to severe offline declines, while e-commerce remains strong. Beauty Farm, as a platform, avoided offline risks, with 2025 net profit over ¥340 million (up 34%).

2. Beauty Farm acquired Siyanli to expand into the top three and launched high-end collaborations like Shiseido’s, offering partnership opportunities for new brands in salon channels.

3. Platforms should learn from Beauty Farm’s profit growth (revenue up 16%) while managing price wars and channel imbalances. Offline instability is a risk, but premiumization offers a direction for high-value focus.

The article analyzes industry shifts, emerging issues, and business models.

1. New trends include accelerated premium cosmetics demand, highlighted in Shiseido’s reports. Beauty Farm’s Siyanli acquisition created a top-three player (revenue up 16%), signaling industry consolidation.

2. Emerging issues: offline channels fell steadily (double-digit quarterly declines), contrasting with e-commerce growth. Shiseido’s net loss widened, yet China remained its highest-profit region, suggesting policy support for self-help measures.

3. Business models like Shiseido-Beauty Farm partnerships and RQ Lüyao’s premium positioning offer case studies for researching industry impact and replicability.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】日前,资生堂旗下科技护肤品牌RQ律曜与美丽田园达成合作,首次进入院线渠道。

同时,资生堂集团官宣与美丽田园达成战略合作。双方联合推出“光感透白”高端护理项目,并于3月6日登陆美丽田园核心门店。

资生堂旗下品牌进驻美容院,是一场针对线下渠道和高端化战略的紧急“自救”。

从整体财报来看,资生堂仍处于收缩周期:2025年净销售额为9,699.92亿日元,同比收缩2.08%;归母净亏损406.8亿日元,同比下降276.21%。

然而,财报中并非全无希望:销售成本为2,269.89亿日元,同比收缩4.38%,已连续三年下降;毛利率达76.60%,为近六年最高;核心营业利润为445.2亿日元,同比增长22.45%。

收缩的重要原因,是其中国及旅游零售业务:销售额为3,422.44亿日元,同比下跌155亿日元,加上美洲市场下跌的120亿日元,几乎“承包”了集团全年销售额的缩减(共计205.94亿元)。

然而,从核心营业利润来看,中国市场仍是资生堂不得不“救”的关键:中国及旅游零售业务的核心营业利润为645.25亿日元,虽同比下跌75亿日元,但该业务仍是资生堂核心利润最高的板块。

从2025年四个季度的财报来看,线下渠道是资生堂在中国市场的重要拖累:仅第三季度实现低个位数增长,第一季度、第二季度下滑幅度达两位数,第四季度下滑幅度为低个位数。相比之下,电商渠道全年实现增长。即便主品牌SHISEIDO电商表现强劲,但前三季度线下渠道仍同比下滑。

高端化则是资生堂在中国市场的第二个关键词。自第二季度以来,资生堂在财报中不断提及高端化妆品增速加快。虽然双11期间价格战激烈,但第四季度的增长由高端品牌带动。

再看RQ律曜。通过与美丽田园的合作,其恰好撞在了资生堂在中国市场“重振线下”和“高端化”的两个痛点上。

据报道,RQ律曜是资生堂在中国市场推出的本土化品牌,科研背靠上海第九人民医院与创健医疗。目前,品牌拥有医美和护肤两条产品线。其中,重组胶原蛋白是其医美线的主要原料,价格在249元至9,900元不等。护肤品线涵盖卸妆、修护、抗老、美白、防晒等功能,单品价格基本在480元及以上。

美丽田园在线下美容领域已形成一定的龙头地位。2025年,美丽田园以12.5亿元收购思妍丽100%的股份,进一步扩充线下版图。据悉,目前美丽田园麾下的“美丽田园、奈瑞儿、思妍丽”已占据中国美容行业前三席位,后两者均已被美丽田园收购。

此前,美丽田园发布2025全年正面盈利预告:收入超30亿元,同比增长超16%;经调整净利润超3.8亿元,同比增长超40%;净利润超3.4亿元,同比增长超34%。

亿邦持续追踪报道该情报,如想了解更多与本文相关信息,请扫码关注作者微信。

文章来源:亿邦动力

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0